Latest news with #NovaSeqXPlus
Time of India
5 days ago
- Business
- Time of India
Dr. Lal PathLabs adds Illumina's NovaSeq X Series to expand genomics capabilities
Mumbai: Diagnostic provider Dr. Lal PathLabs Limited (DLPL) has expanded its genomics division, Genevolve , with the addition of Illumina 's NovaSeq X Series . The integration is expected to enhance the lab's capacity to deliver faster and more accurate genomic insights . The NovaSeq X system incorporates Illumina's XLEAP-SBS chemistry, offering high throughput, improved accuracy, and increased efficiency. It is stated that The NovaSeq X Plus model can process over 20,000 whole genomes per year—more than twice the capacity of Illumina's earlier models. The system is designed to support large-scale genomic research through increased speed and sensitivity. According to DLPL, the investment supports its broader efforts to improve genomic testing capabilities and contribute to the country's growing genomics landscape. Launched in 2019, DLPL's Genevolve unit focuses on DNA-based diagnostics and next-generation sequencing (NGS). The addition of Illumina's technology is expected to further strengthen its offerings in this space. Dr. Lal PathLabs and Illumina also plan to collaborate with India's scientific and medical communities to promote awareness and capacity-building for genomics-based healthcare.
Business Standard
6 days ago
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Business Upturn
6 days ago
- Business
- Business Upturn
Dr. Lal PathLabs boots genomics capabilities with Illumina's NovaSeq™ X Series
By Aman Shukla Published on June 25, 2025, 11:39 IST Dr. Lal PathLabs Limited (DLPL), one of India's most trusted names in diagnostics, has taken a major step forward in genomics by adding the advanced NovaSeq™ X Series from Illumina to its dedicated genomics unit, Genevolve. This cutting-edge technology allows DLPL to deliver faster and more accurate results in genetic research. The NovaSeq™ X system, powered by Illumina's XLEAP-SBS™ chemistry, offers top-notch performance with high speed, accuracy, and sustainability. In fact, the NovaSeq X Plus can handle over 20,000 whole genomes per year—twice as much as earlier models. Genevolve, launched in 2019, has quickly made a name for itself as a leader in DNA-based diagnostics and next-generation sequencing (NGS). With the new Illumina platform onboard, DLPL is now even better equipped to offer quick, AI-driven insights that can support smarter healthcare decisions. 'With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,' said Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. 'This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.' Looking ahead, Dr. Lal PathLabs and Illumina plan to work closely with India's medical and research communities to promote the use of genomics in healthcare, helping unlock new possibilities in personalized medicine. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
